Association of AR V7 on Circulating Tumor Cells as a Treatment Specific Biomarker With Outcomes and Survival in Castration Resistant Prostate Cancer.
Importance A critical decision in the management of metastatic castration resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane. Objective To determine if pretherapy nuclear androgen receptor splice variant 7 (AR V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment specific marker for response and outcomes between ARS inhibitors and taxanes. Design, Setting, and Participants For this cross sectional cohort study at Memorial Sloan Kettering Cancer Center, 265 men with progressive mCRPC undergoing a change in treatment were considered; 86 were excluded because they were not initiating ARS or taxane therapy; and 18 were excluded for processing time constraints, leaving 161 patients for analysis. Between December 2012 and March 2015, blood was collected and processed from patients with progressive mCRPC immediately prior to new line of systemic therapy. Patients were followed up to 3 years. Main Outcomes and Measures Prostate specific antigen (PSA) response, time receiving therapy, radiographic progression free survival (rPFS) and overall survival (OS) Results Overall, of 193 prospectively collected blood samples from 161 men with mCRPC, 191 were evaluable (128 pre ARS inhibitor and 63 pretaxane) AR V7 positive CTCs were found in 34 samples (18% including 3% of first line, 18% of second line, and 31% of third or greater line samples. Patients whose samples had AR V7 positive CTCs before ARS inhibition had resistant posttherapy PSA changes (PTPC) shorter rPFS, shorter time on therapy, and shorter OS than those without AR V7 positive CTCs. Overall, resistant PTPC were seen in 65 of 112 samples (58% without detectable AR V7 positive CTCs prior to ARS inhibition. There were statistically significant differences in OS but not in PTPC, time on therapy, or rPFS for patients with or without pretherapy AR V7 positive CTCs treated with a taxane. A multivariable model adjusting for baseline factors associated with survival showed superior OS with taxanes relative to ARS inhibitors when AR V7 positive CTCs were detected pretherapy (hazard ratio, 0.24; 95% CI, 0.10 0.57; P .035) Conclusions and Relevance The results validate CTC nuclear expression of AR V7 protein in men with mCRPC as a treatment specific biomarker that is associated with superior survival on taxane therapy over ARS directed therapy in a clinical practice setting. Continued examination of this biomarker in prospective studies will further aid clinical utility.
JAMA oncology